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Circulating autoantibodies to self-antigens overexpressed by cancer cells are common in cancer patients. As specific proteins
are expressed during neoangiogenesis, a similar phenomenon might occur with particular antigens of tumour vessels. Collagen XVIII,
from which endostatin is cleaved, is highly expressed in the perivascular basement membrane of tumour-associated blood vessels
and autoantibodies to endostatin have been reported in cancer patients. The present study analyses the incidence of naturally
occurring autoantibodies to endostatin in the sera of breast cancer patients and their relation to endostatin serum levels and patient
clinical outcome. Serum samples from 36 patients with localised breast cancer and 59 patients with a fully documented history
of metastatic breast cancer were used. The immunoreactivity of serum samples was tested against purified recombinant
human endostatin and endostatin levels were determined by immunoassay. We could detect anti-endostatin antibodies in the sera of
66% of the patients with localised disease and 42% of the patients with metastatic disease (P¼0.03). There was no correlation
between the presence of antibodies to endostatin and circulating levels of endostatin. The detection of autoantibodies to endostatin
was associated with better prognosis in metastatic breast cancer patients (median survival time: 20 vs 8 months, P¼0.03), as was
the presence of low levels of serum endostatin (median survival time: 20 vs 9 months, P¼0.007). These results show that a natural
immune reaction against endostatin can occur in breast cancer patients. This could have important therapeutic implications
with regard to endostatin therapy and raises the question of a possible role of this humoral reaction against endostatin in the
neoplastic process.
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Autoantibodies are frequently observed in the sera of patients
with malignancies and their titres have been correlated to patients’
survival or other clinicopathological parameters (Soussi, 2000; von
Mensdorff-Pouilly et al, 2000). Cancer-related autoimmunity often
appears to be directed against mutant forms of proteins or is
associated with the overexpression of autoantigens in autologous
tumour cells (Boon and Old, 1997; Soussi, 2000). As specific
proteins are expressed during neoangiogenesis, a similar pheno-
menon might occur with particular antigens of tumour vessels.
Endostatin, one of the most potent known natural inhibitors of
angiogenesis (O’Reilly et al, 1997), is a C-terminal fragment of
collagen XVIII, which is mainly localised in the basement
membrane zones of the vessels (Muragaki et al, 1995), particularly
in newly formed, tumour-associated blood vessels (St Croix et al,
2000). Elevated serum levels of endostatin have been found in
metastatic cancer patients (Feldman et al, 2002) and have been
correlated to the clinical course of the disease and to tumour
vascularity in various tumour types (Bono et al, 2003). We
have previously described autoantibodies to endostatin in several
patients with cancer (Ratel et al, 2000) and have been able to
show the existence of both circulating and tumour endostatin
autoantibodies.
This study was undertaken to investigate the possible presence
of autoantibodies to endostatin in the sera of breast cancer
patients, as well as its relation to endostatin serum levels and
patient clinical outcome.
PATIENTS AND METHODS
Patients and controls
This study includes 59 patients with metastatic breast cancer,
36 patients with localised breast cancer and 24 healthy women as
control subjects. After obtaining patient informed consent, serum
samples were collected, aliquoted and stored at  801C. All
serum samples were kept frozen at  801C, then thawed shortly
before use. Metastatic breast cancer patients were treated at our
institution between January 1995 and November 2000, and their
main characteristics are shown in Table 1. The 36 patients with
localised breast cancer were treated at our institution between
November 1994 and June 2003; they had stage 1 breast cancer (11
patients), stage 2 breast cancer (13 patients) or stage 3 breast
cancer (12 patients). The median age was 56 years (range 33–85).
In all cases, serum sampling was performed at the time of surgery.
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sThe control subjects for autoantibody prevalence were 24 healthy
women, with a median age of 53 years (range 28–59). The sera of
16 additional healthy women were used as control for normal
endostatin levels.
Immunoreactivity of serum samples against recombinant
human endostatin
Recombinant human endostatin was produced in yeast (Pichia
pastoris) as a single polypeptide having a total molecular mass of
20000Da (France Biochem, Meudon, France). The amino-acid
sequence of recombinant human endostatin was in total agreement
with the expected amino-acid composition of the native
human endostatin. In all, 1mg of purified recombinant human
endostatin was loaded into wells of a 10% sodium dodecyl
sulfate–polyacrylamide gel, then electrophoresis was performed.
The gel was blotted onto a polyvinylidene fluoride membrane
(PVDF, Millipore, Saint Quentin, France). The blot was blocked in
Tris-buffered saline (TBS)–10% non-fat milk. Polyvinylidene
fluoride membrane strips were cut and separately reacted
overnight at 41C with each healthy donor’s or patient’s serum
sample at a ratio of 1/100. The strips were washed three times,
blocked in TBS–5% non-fat milk, and reacted with goat antibodies
to human IgG conjugated to horseradish peroxidase (Sigma, Saint
Quentin Fallavier, France). After washing, the blot was developed
with diaminobenzidine substrate (Vector Laboratories, Burlin-
game, CA, USA). The positive control was human endostatin
exposed to antibodies to murine endostatin (R&D System,
Abingdon, UK).
Western blot analysis of serum endostatin
A volume of 100ml of each serum sample was treated at 41C with
SwellGel Blue Albumin Removal Kit (Pierce, Rockford, IL, USA)
according to the manufacturer’s instructions. The filtrate was then
collected, and protein content was quantified by a Bradford assay
(Protein Assay; BioRad, Munich, Germany). Serum protein
(100mg) was separated by sodium dodecyl sulphate–polyacryla-
mide gel electrophoresis (12% polyacrylamide) under reducing
conditions and transferred to a PVDF membrane (Protran;
Schleicher and Schuell, Dassel, Germany). The membrane was
then blocked in 10% nonfat milk in TBS for at least 30min, then
incubated overnight at 41C with rabbit anti-human endostatin
polyclonal antibody (Oncogene Research Products, San Diego, CA,
USA) in 3% BSA/TBS-Tween. After washing, PVDF membranes
were incubated for 2h with a horseradish peroxidase-conjugated
antirabbit IgG antibody (BioRad). Signals were developed using
the chemiluminescent detection kit (ECL plus Western Blotting
Detection System; Amersham Pharmacia Biotech, Buckingham-
shire, UK) as indicated by the supplier. Bands on microfilm
(Hyperfilm, Amersham Pharmacia Biotech) were scanned.
Determination of endostatin serum levels
Serum endostatin protein levels were determined by a competitive
enzyme immunoassay in which the amount of biotinylated
endostatin captured by the antibody decreased as the concentra-
tion of endostatin in the serum increased. The assay was then
visualised using a streptavidin alkaline phosphatase conjugate and
an ensuing chromagenic substrate reaction (Accucyte
s human
endostatin kit from Cytimmune Sciences Inc., College Park, MD,
USA). All serum level determination experiments were performed
in triplicates. The detection limit of the test was 1.95ngml
 1; lower
levels were considered undetectable.
Statistical analysis
Statistical analyses were carried out according to the procedures
of the SPSS
s package 8.0 (Chicago, IL, USA, 1999). Patient
characteristics were compared using Student’s t-test for quantita-
tive variables. Contingency tables were analysed using Pearson’s w
2
test. Survival data, considered from the day of sampling to the time
of death or the time of last follow-up, were assessed by means of
the Kaplan–Meier method.
RESULTS
Circulating antibodies to endostatin in breast cancer
patients
The presence of endostatin autoantibodies in the serum was
examined using a Western blotting approach in which immobi-
lised recombinant human endostatin was incubated with the sera
of healthy controls or of patients with metastatic breast cancer.
An example of such experiments is shown in Figure 1. Antibodies
to endostatin were detected in the sera of 24 out of 36 patients
with localised breast cancer (66%), 25 out of 59 patients with
metastatic breast cancer (42%), and 4 out of 24 healthy women
(16%). Differences were statistically significant (w
2¼12, Po0.0001
between all breast cancer patients and controls; w
2¼5.2, P¼0.03
between localised and metastatic breast cancer patients).
Circulating endostatin in the sera of breast cancer patients
As the appearance of autoantibodies can be attributable to a
change in the status of the protein during carcinogenesis (Soussi,
2000), we searched whether serum endostatin levels were altered in
metastatic breast cancer patients. Circulating serum endostatin
Table 1 Metastatic patient characteristics
Characteristics No. of patients %
Entered on study 59 100
Age (years)
Median 54
Range 26–83
PS
0–1 41 69.5
2–4 18 30.5
Receptor status (four missing values)
ER positive 39 71
ER negative 16 29
Adjuvant chemotherapy
Received 28 47.5
Not received 31 52.5
Prior chemotherapy for metastatic disease
Received 41 69.5
Not received 18 30.5
Disease-free interval (months)
o24 27 46
424 32 54
Metastatic site
Liver 36 61
Lung 27 46
One or two 34 58
Three or more 25 42
Lymphocyte count (10
6cellsl
 1)
Median 905
Range 100–2700
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swas found detectable in most patients tested (88%), with a median
of 17ngml
 1 (range 0–47). By comparison, the 16 control subjects
had a median serum level of endostatin of only 7ngml
 1 (range
1–51), but this difference was not statistically significant (P¼0.5).
Whereas multiple C-terminal fragments of collagen XVIII have
been detected in the human circulation and may not necessarily
exhibit antiangiogenic activities (Sasaki et al, 2002), we performed
additional Western blot analyses on 12 samples to identify soluble
endostatin molecules. A specific endostatin band (around 21kDa)
was detected, thus corroborating the data obtained by competitive
EIA (Figure 2).
Correlation to the clinical characteristics of metastatic
breast cancer patients
The detection of serum autoantibodies to endostatin was
correlated to better survival in metastatic breast cancer patients.
The median survival time of the 25 patients with detectable serum
autoantibodies to endostatin was 20 months, vs 7 months for the
other 34 patients (P¼0.03, Figure 3A). As different threshold
values of serum endostatin, particularly 36ngml
 1, have been
described as being correlated to survival (Bono et al, 2003), we
examined the prognosis of patients with high levels of serum
endostatin. The 48 patients whose serum endostatin was below
36ngml
 1 had a significantly better survival than the 11 patients
whose endostatin level was above this value (median survival time
12 vs 7 months, P¼0.007, Figure 3B). When the median serum
concentration of endostatin was used as a threshold (17ngml
 1),
the patients within the low-level group had a median survival of
19 months, whereas the 30 patients within the high-level group
had a median survival of 11 months, but this difference was not
statistically significant (P¼0.5).
As cancer-induced immunosuppression could interfere with
immune response against endostatin, we assessed a possible
correlation between the lymphocyte count and the detection of
autoantibodies to endostatin in metastatic breast cancer patients
(one missing value). Fifteen patients had normal lymphocyte
count (i.e. X1.5Gl
 1), of whom 10 (66.6%) had detectable
serum levels of autoantibodies to endostatin. By contrast, the
serum of only 14 of 43 patients (32.5%) with a lymphocyte count
below 1.5Gl
 1 showed immunoreactivity against endostatin
(w
2¼5.3, P¼0.03).
Collagen XVIII is particularly abundant in the liver, so we
assessed whether patients with liver metastases had higher levels of
serum endostatin or incidence of autoantibodies. This was not the
case. The median serum level of endostatin in the 36 patients with
liver metastases was 18ngml
 1 (range 0–47) vs 15ngml
 1 (range
0–45) in the 23 patients without liver metastasis. This difference
was not significant (P¼0.8). Serum levels of autoatibodies to
endostatin were detectable in 15 of the 36 patients with liver
metastases vs 10 of the 23 patients without liver metastasis
(w
2¼0.2, P¼0.9).
With regard to treatment, this population was too hetero-
geneous to make any relevant correlation between endostatin
serum levels or autoantibody incidence and the chemotherapy
regimen received by the patient.
20 kDa
23456789 1 0 1
Normal
serum
samples
Patients
serum
samples
Anti-
endostatine
Figure 1 Reactivity of serum samples from patients with metastatic
breast cancer, control serum samples and anti-endostatin antibodies
(positive control), with recombinant human endostatin. Western immuno-
blot shows that serum samples from patients 1, 4, 5, 7, 8, 9, 10 and positive
control (anti-endostatin antibodies) were strongly reactive to recombinant
endostatin, whereas serum samples from other patients and from normal
controls were negative.
35 kDa
30 kDa
25 kDa
15 kDa
10 kDa
1 2 3 4 (patients)
(ng/ml)
Endostatin
5.7 11.7 42.6 46.1
Figure 2 Detection of endostatin by Western blot analysis. The sera of
12 patients evaluated for endostatin concentration by ELISA were
separated on polyacrylamide gel and incubated with a specific endostatin
antibody as described in Materials and Methods. Results of four patients are
shown. Marker bands (10, 15, 25, 30 and 35kDa) are depicted. No specific
signal could be detected in the sera with 5.7 and 11.7ngml
 1 of the
inhibitor.
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Figure 3 (A) Survival of patients as a function of the detection of
autoantibodies to endostatin. Kaplan–Meier analysis showed that patients
with detectable endostatin autoantibodies had significantly longer overall
survival (P¼0.03). (B) Survival of patients as a function of serum
endostatin levels. Kaplan–Meier analysis showed that patients with lower
serum endostatin levels had significantly longer overall survival (P¼0.007).
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sDISCUSSION
Our study shows that antibodies to endostatin can be found in the
sera of localised and metastatic breast cancer patients. The
incidence of these autoantibodies is higher in patients with
localised disease, and is associated with a better prognosis in
patients with metastatic disease.
High serum endostatin levels have been described in metastatic
cancer patients and most published studies show that high levels
of the protein are correlated with aggressive disease or poor
prognosis, which is in agreement with our results (Feldman et al,
2002; Bono et al, 2003). We have found no correlation between
endostatin serum levels and the detection of antibodies to
endostatin. The mean endostatin serum level was 18.2ngml
 1
for the 34 patients who did not have detectable levels of antibodies
to endostatin vs 21.5ngml
 1 for the other 25 patients (P¼0.9).
Increased endostatin levels were observed in the sera of some
patients who did not develop autoantibodies, indicating
that additional mechanisms may be required to trigger an
autoimmune response.
The fact that low endostatin serum levels and the presence of
autoantibodies to endostatin are associated with a better survival is
puzzling, as endostatin is supposed to act as an inhibitor of
angiogenesis, tipping the balance of the angiogenic switch towards
the ‘off’ position, thus inhibiting cancer progression. It has been
suggested that angiogenesis-inhibiting and -promoting factors are
both upregulated in aggressive diseases, angiogenesis inhibitors
(like endostatin) being released as a consequence of the activity
of angiogenesis promoters (like VEGF) (Feldman et al, 2002).
Another hypothesis to explain this ‘paradox’ is that elevated
serum endostatin mostly reflects ongoing angiogenesis, as it is
known that (i) matrix metalloprotease, which is activated during
angiogenesis, can cleave collagen and modify its structure (Xu
et al, 2001; Hangai et al, 2002), and (ii) collagen XVIII is mainly
synthesised in the perivascular basement membrane of tumour-
associated blood vessels (Muragaki et al, 1995; St Croix et al, 2000;
Guenther et al, 2001). This can explain that large and aggressive
tumours will generate more soluble endostatin than small ones
(Feldman et al, 2001). Finally, it should be noted that the
functional status of the soluble endostatin detected in this study
has not been ascertained, similar to other studies using the same
competitive EIA (Feldman et al, 2002; Bono et al, 2003).
Overexpression of tumour antigens or expression of cryptic
antigens following structural modification can lead to an improper
immune reaction against this protein (von Mensdorff-Pouilly et al,
2000). Such a phenomenon might explain the presence of
autoantibodies to endostatin in our patients; even so, endostatin
may be expressed mostly by tumour-associated stromal cells. This
hypothesis is supported by our previous work in glioma patients in
which we reported an intense endostatin immunoreactivity in
tumour vessels, along with immunoglobulin deposits in the same
areas (Ratel et al, 2000).
The role of autoantibodies to tumour antigens in the neoplastic
evolution is a matter of debate. Such antibodies may have an
important activity in the neoplastic process. Experiments con-
ducted on several preclinical models have shown that an immune
reaction against tumour blood vessels may lead to tumour
regression (Brooks et al, 1995). One can assume that an immune
response directed against the tumour vasculature may slow down
tumour progression in these patients and partially explain their
better survival. This hypothesis is further supported by in vivo
results obtained in animal models in which monoclonal antibodies
to cryptic sites within collagen IV lead to inhibition of angiogen-
esis and tumour growth (Xu et al, 2001).
On the other hand, the presence of autoantibodies to endostatin
may mostly reflect general auto-immunity against tumour-
associated antigens (Soussi, 2000). This would explain the higher
prevalence of such antibodies in localised cancer and their absence
in the sera of patients with the worst prognosis, which could be
related to nonspecific tumour-associated immunosuppression
(Ray-Coquard et al, 2001; Treilleux et al, 2004). This hypothesis
is further supported by the correlation we have shown between low
lymphocyte counts and the absence of autoantibodies to endo-
statin.
Finally, the fact that autoantibodies to endostatin could be
present in the sera of metastatic breast cancer patients may have
important implications for recombinant endostatin treatments as
those antibodies could interact with the recombinant protein. Such
antibodies have been described in a clinical trial of recombinant
human endostatin in which they were not associated with changes
in endostatin pharmacokinetic (Thomas et al, 2003). However, the
goal of this phase I clinical trial was not to assess clinical efficacy,
and no response was observed. One cannot rule out a possible
interaction between recombinant endostatin and pre-existing
serum autoantibodies to endostatin, leading to a deterioration of
its clinical efficacy.
In conclusion, this study shows that autoantibodies to endo-
statin can be detected in the sera of breast cancer patients and
that the presence of such antibodies is associated with better
survival in metastatic disease. Additional preclinical and clinical
studies are warranted to understand the clinical importance of the
humoral response to endostatin in breast cancer patients with
regard to tumour progression and therapeutic implications.
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